DermTech
DermTech 2.0 is a US-based skin genomics platform that commercializes the DermTech Melanoma Test, a non-invasive Smart Sticker-based qPCR assay measuring LINC00518 and PRAME to help dermatologists rule out melanoma, and offers DermTech Stratum biomarker services to biopharma and research partners.
- Company typePrivate
- Founded1996
- HeadquartersLa Jolla, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What DermTech does
DermTech 2.0 (operating as DermTech, LLC) is a US-based skin genomics platform company headquartered in San Diego, California, with a CLIA-certified, Joint Commission-accredited laboratory. The company develops and commercializes the DermTech Melanoma Test (Pigmented Lesion Assay®), a physician-ordered laboratory-developed test that uses proprietary Smart Sticker® adhesive patches to painlessly collect skin cells from pigmented lesions for RNA gene expression analysis of LINC00518 and PRAME markers, delivering a reported 99% negative predictive value to support dermatologists' biopsy decisions. DermTech serves dermatology practices and their patients across the United States, with Medicare LCD #38151 coverage providing $0 out-of-pocket costs for eligible beneficiaries and additional billing through Tricare and commercial insurers. A second line of business, DermTech Stratum, provides precision biomarker services — including clinical trial support, genomic analysis, and tissue banking — to biopharmaceutical and research partners.
Revenue is generated primarily through per-test insurance billing under a one-time laboratory testing model, supplemented by professional services revenue from Stratum biopharma engagements. The go-to-market is an enterprise field sales motion into dermatology practices, supported by a physician portal, customer service onboarding, and inclusion in the NCCN Clinical Practice Guidelines for Melanoma: Cutaneous. Following an August 2024 asset sale, the company operates under new ownership (James E. Stowers III, Chairman; Burkhard Jansen, M.D., President), with leadership focused on rebuilding the diagnostic franchise and expanding the Stratum services platform for biopharma drug discovery in cancers and inflammatory diseases.
DermTech firmographics
Firmographics- Name
- DermTech
- Legal name
- DermTech, LLC
- Website
- https://dermtech.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DermTech 2.0 is a US-based skin genomics platform that commercializes the DermTech Melanoma Test, a non-invasive Smart Sticker-based qPCR assay measuring LINC00518 and PRAME to help dermatologists rule out melanoma, and offers DermTech Stratum biomarker services to biopharma and research partners.
- Ownership category
- akta.pro rank
DermTech industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Dermatopathology (HLAKACAC)
Keywords
Where DermTech is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DermTech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Testing Services: The DermTech Melanoma Test is a physician-ordered laboratory-developed test. Revenue generated through insurance billing to Medicare, Tricare, and commercial insurers. Patients may have $0 out-of-pocket costs for Medicare-covered tests.
- Clinical Trial Support Services (DermTech Stratum): Services for biopharma and research partners including complete trial management, site access, and genomic analysis of skin samples collected via Smart Stickers. Revenue from pharmaceutical research partnerships and tissue bank services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Medicare patients - $0 out-of-pocket |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
DermTech product offering
Product offeringCore offering
DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker adhesive patches. Its primary commercial offering is the DermTech Melanoma Test (Pigmented Lesion Assay), a physician-ordered laboratory-developed test that analyzes LINC00518 and PRAME gene expression markers to aid dermatologists in biopsy decisions for pigmented lesions. The company also operates DermTech Stratum, a precision biomarker services platform offering clinical trial support, genomic analysis of skin samples, and tissue banking for biopharmaceutical and research partners.
Product overview
DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Stickers. The core offering is the DermTech Melanoma Test (also known as the Pigmented Lesion Assay), which detects genomic markers associated with melanoma to aid dermatologists in biopsy decisions. The company also offers DermTech Stratum, a separate platform providing precision biomarker services for biopharmaceutical and research partners, including clinical trial support services. The Smart Stickers serve as the foundational collection technology that enables both the diagnostic test and research services.
Differentiator
Problem solved
Functional benefit
Brands
- DermTech Melanoma Test: Non-invasive genomic test for melanoma detection using Smart Sticker technology with 99% NPV.
- DermTech Stratum
- Smart Sticker
- Pigmented Lesion Assay
Products and services
- DermTech Melanoma Test (Pigmented Lesion Assay) Physician-ordered laboratory-developed test that analyzes RNA expression of LINC00518 and PRAME markers in skin cells collected non-invasively via Smart Sticker to rule out melanoma in pigmented lesions meeting ABCDE criteria. Performed at the company's CLIA-certified laboratory with results returned in approximately 5 business days.
- DermTech Stratum Precision biomarker services platform for biopharmaceutical and research partners offering non-invasive skin genomics services, clinical trial support including complete trial management and site access, genomic analysis of skin samples collected via Smart Stickers, and curated tissue bank access for drug discovery in cancers and inflammatory diseases.
Quantifiable outcome
- 99% negative predictive value (NPV) for melanoma rule-out
- +3 more outcomes
Companies that use DermTech
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
DermTech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
DermTech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Biopharma and research partners (unspecified)coreDermTech Stratum platform expanded to include clinical trial support services targeting biopharma and research partners. Services include complete trial management, site access, and genomic analysis of skin samples collected via Smart Stickers. The company emphasizes its curated tissue bank and platform suitability for drug discovery related to cancers and inflammatory diseases.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
DermTech competitors and assessment
Company assessmentDirect peers
- Castle Biosciences: Castle Biosciences markets DecisionDx-Melanoma, a molecular prognostic test for cutaneous melanoma — the most direct head-to-head competitor to the DermTech Melanoma Test in dermatology practices.
- Veracyte: Veracyte is a molecular diagnostics company offering gene-expression-based tests in oncology, with a similar physician-channel, evidence-driven commercial model to DermTech.
- Interpace Biosciences: Interpace is a specialty molecular diagnostics company offering physician-ordered, insurance-reimbursed lab tests in oncology — sharing the LDT commercial model DermTech uses.
Broad incumbents
- Myriad Genetics: Myriad is an established molecular diagnostics company operating across oncology (including dermatology-adjacent indications), sharing the same specialty-lab, insurance-reimbursed commercial model as DermTech.
- NeoGenomics: NeoGenomics provides oncology-focused molecular and genetic testing services with a CLIA lab network, broadly comparable in scale and payor-driven reimbursement model to DermTech.
- Quest Diagnostics: Quest is one of the largest US clinical reference laboratories with a dermatopathology and molecular diagnostics franchise that overlaps with DermTech's lab services.
- Labcorp: Labcorp operates a national clinical and specialty lab network with dermatopathology and oncology molecular services, serving the same physician customer base as DermTech.
Emerging players
- Skin Analytics: Skin Analytics uses AI-based image analysis for melanoma triage in dermatology and primary care, representing a non-invasive alternative route to the same melanoma rule-out use case DermTech targets.
- Strata Skin Sciences (MelaFind legacy): Strata inherited the MelaFind non-invasive melanoma detection platform; while a different technology (optical/spectroscopic), it targets the same dermatology melanoma triage use case.
- Dermasensor: Dermasensor is developing a non-invasive spectroscopy-based device for skin cancer triage in primary care, addressing an overlapping melanoma rule-out use case.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
DermTech social profiles
Digital presenceDermTech compliance and trust
Trust signalCompliance3 records
DermTech financial estimates
Financial estimateRevenue estimate
Valuation estimate
DermTech leadership team
Management profileNumber of profiles
Profiles6 records
DermTech funding detail
Funding detailFunding overview
Funding rounds11 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DermTech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DermTech
What does DermTech do?
DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker adhesive patches. Its primary commercial offering is the DermTech Melanoma Test (Pigmented Lesion Assay), a physician-ordered laboratory-developed test that analyzes LINC00518 and PRAME gene expression markers to aid dermatologists in biopsy decisions for pigmented lesions. The company also operates DermTech Stratum, a precision biomarker services platform offering clinical trial support, genomic analysis of skin samples, and tissue banking for biopharmaceutical and research partners.
Is DermTech a public or private company?
DermTech is a private company. It is classified as unknown and is currently operating.
When was DermTech founded?
DermTech was founded in 1996. It employs 11 to 50 people.
Where is DermTech based?
DermTech is headquartered in La Jolla, United States, in the North America region.
How does DermTech make money?
Two revenue lines are on record. Laboratory Testing Services are the primary driver. The others are clinical Trial Support Services (DermTech Stratum).
Who are DermTech's main competitors?
Direct peers on record are Castle Biosciences, Veracyte and Interpace Biosciences. Broad incumbents are Myriad Genetics, NeoGenomics, Quest Diagnostics and Labcorp. Emerging players are Skin Analytics, Strata Skin Sciences (MelaFind legacy) and Dermasensor.
Does DermTech have an API?
No public API is recorded for DermTech.
What industry is DermTech in?
DermTech's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.